Alkermes (ALKS) Return on Capital Employed (2011 - 2026)
Alkermes' (ALKS) quarterly Return on Capital Employed came in at 6.92% in Q1 2026, down 1715.0% year-on-year from 0.43% in Q1 2025, and down 49.19% on a QoQ basis from 13.62% in Q4 2025.
Alkermes (ALKS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Return on Capital Employed data on file, last reported at 6.92% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1715.0% year-over-year to 6.92% in Q1 2026; TTM through Mar 2026 was 6.92%, a 1715.0% decrease from a year earlier, with the FY2025 full-year figure at 14.7%, down 1110.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.92%, down from 13.62% in the prior quarter.
- Over the last five years, Return on Capital Employed for ALKS reached as high as 28.03% in Q1 2024 and fell as low as 0.42% in Q4 2022.
- Historically, Return on Capital Employed has averaged 15.24% across 5 years, with a median of 18.1% in 2024.
- Across the five-year window, Return on Capital Employed jumped 2737 bps in 2024 and sank 1715 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 0.42% in 2022, then soared by 5965 bps to 24.54% in 2023, then climbed by 5 bps to 25.64% in 2024, then sank by 47 bps to 13.62% in 2025, then plunged by 49 bps to 6.92% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 6.92% in Q1 2026, 13.62% in Q4 2025, and 19.73% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 6.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.92% |
| Dec 31, 2025 | 13.62% |
| Sep 30, 2025 | 19.73% |
| Jun 30, 2025 | 22.52% |
| Mar 31, 2025 | 24.07% |
| Dec 31, 2024 | 25.64% |
| Sep 30, 2024 | 18.10% |
| Jun 30, 2024 | 18.00% |
| Mar 31, 2024 | 28.03% |
| Dec 31, 2023 | 24.54% |
| Sep 30, 2023 | 27.46% |
| Jun 30, 2023 | 20.75% |
| Mar 31, 2023 | 0.66% |
| Dec 31, 2022 | -0.42% |
| Sep 30, 2022 | 0.52% |
| Jun 30, 2022 | 3.19% |
| Mar 31, 2022 | 5.69% |
| Dec 31, 2021 | 6.35% |
| Sep 30, 2021 | -4.12% |
| Jun 30, 2021 | -3.50% |